Chronic GVHD and Management of its Sequelae

慢性 GVHD 及其后遗症的处理

基本信息

批准号：
10679975
负责人：
SUNG WON CHOI
金额：
$ 2.2万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-04-19 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10679975
关键词：
Administrator Adolescent and Young Adult Adult Affect Allogenic American Area Award Basic Science Biometry Canada Cell Therapy Cellular biology Child Child Care Childhood Classification Clinical Clinical Research Clinical Trials Code Collaborations Dedications Development Diagnosis Donor Selection Education Ensure Ethics Etiology Evaluation Family Functional disorder Future Geographic Locations Grant Health Health Professional Healthcare Heart Diseases Hematological Disease Hematology Immunologics Immunology Individual Institution International Knowledge Laboratory Technicians Lead Leadership Letters Life Expectancy Long-Term Survivors Lung Lung diseases Malignant - descriptor Medical Medical Students Mentors Mentorship Midwestern United States Minority Groups Mission Molecular Biology Monitor Morbidity - disease rate National Cancer Institute National Heart, Lung, and Blood Institute Non-Malignant Nurse Practitioners Nurses Oncology Oral Organ Patients Pediatric Hematology Persons Physician Assistants Physicians Prevention Quality of life Research Research Personnel Science Scientific Advances and Accomplishments Scientist Severities Site Societies Specialist Standardization Testing Texas Training Translational Research Transplant Recipients Travel Underrepresented Minority Underrepresented Populations United States National Institutes of Health Vagina anticancer research chronic graft versus host disease clinical investigation curative treatments follow-up forging graduate student hematopoietic cell transplantation improved innovation interest meetings member mortality novel strategies novel therapeutics posters professor programs stem stem cell biology success survivorship symposium transplantation therapy

项目摘要

PROJECT SUMMARY We propose to organize and conduct the Tenth (10th) Annual Pediatric Transplant and Cellular Therapy Consortium (PTCTC) Meeting at the Fort Worth Convention Center in Fort Worth, TX, on May 09, 2023. A unique aspect of the Annual PTCTC Educational Meeting is that it is jointly held with the international American Society of Pediatric Hematology Oncology Conference (May 10–13, 2023) and includes a Combined Plenary Session, bringing pediatric hematology oncology professionals together from around the world. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for childhood hematological conditions. Advances in basic, translational, and clinical research have significantly increased the number of long-term survivors. The remarkable success is owed in part to the presentation, dissemination, and sharing of new knowledge at annual meetings. However, none is solely dedicated to pediatric HCT. A significant problem in the field is chronic graft- versus-host disease (cGVHD). Despite cure, cGVHD is the leading cause of late morbidity and mortality. With their longer life expectancy, a critical need exists to understand the etiology, prevention, development, and diagnosis, and systematically evaluate and monitor cGVHD in children. The 10th Annual PTCTC Educational Meeting will convene clinicians and scientists who will present on the immunologic mechanisms leading to the initiation and development of cGVHD. This will provide a platform that stimulates how to implement systematic cGVHD assessments in a busy clinical setting. In doing so, innovative clinical strategies can be developed and tested across multi-site collaborations and networks, including novel therapeutics for pediatric-specific cGVHD clinical trials. This 1-day program will invigorate the field of pediatric HCT. The primary objectives include I) identify optimal donor selection strategies that can be standardized and implemented irrespective of the treating institution; II) systematically conduct comprehensive cGVHD assessments that accurately classify individual organ and global organ severity at baseline and in follow-up irrespective of the evaluator; III) to review the ‘state of the science’ in cGVHD immunology and management of affected organ dysfunctions (e.g., pulmonary, ocular, vaginal); IV) to enhance the understanding of wellness, thereby maximizing long-term quality-of-life and survivorship of pediatric HCT patients; and V) to promote networking and collaboration of research and clinical24 trials involving pediatric HCT patients. The results of the 10th Annual PTCTC Educational Meeting will likely enhance our understanding of the basic, translational, and clinical state of the scientific research in pediatric- specific cGVHD, which will provide an opportunity and platform to engage young and senior clinicians and scientists to develop collaborative research. The Organizing Committee will make every effort to enhance diversity by increasing individuals from diverse backgrounds, including those from underrepresented groups. Participation of trainees and underrepresented minorities is especially encouraged through travel awards.

项目概要我们建议组织并开展第十届年度小儿移植和细胞治疗联盟 (PTCTC) 会议于 2023 年 5 月 9 日在德克萨斯州沃思堡会议中心举行。年度 PTCTC 教育会议的一个特点是它是与国际美国学会联合举办的儿科血液肿瘤学会议（2023 年 5 月 10-13 日），包括联合全体会议，将来自世界各地的儿科血液肿瘤学专业人士聚集在一起。细胞移植（HCT）是治疗儿童血液疾病的一种潜在疗法。基础、转化和临床研究显着增加了长期幸存者的数量。显着的成功部分归功于每年一次的新知识的展示、传播和分享然而，没有一个会议专门讨论儿科 HCT，该领域的一个重要问题是慢性移植。尽管可以治愈，但 cGVHD 仍是晚期发病和死亡的主要原因。他们的预期寿命更长，迫切需要了解其病因、预防、发展和诊断，并系统评估和监测儿童 cGVHD 第 10 届年度 PTCTC 教育活动。会议将召集超级明星和科学家，他们将介绍导致这一疾病的免疫机制。 cGVHD的启动和发展这将为促进如何实施系统化提供一个平台。在繁忙的临床环境中进行 cGVHD 评估，可以制定和实施创新的临床策略。在多站点合作和网络中进行了测试，包括针对儿科特异性 cGVHD 的新疗法这个为期 1 天的计划将振兴儿科 HCT 领域，主要目标包括 I)。确定最佳的供体选择策略，这些策略可以标准化并实施，无论治疗如何机构；II) 系统地进行全面的 cGVHD 评估，对个体进行准确分类无论评估者如何，基线和随访中的器官和整体器官严重程度 III) 审查“状态”； cGVHD 免疫学和受影响器官功能障碍（例如肺、眼、阴道）；IV）增强对健康的理解，从而最大限度地提高长期生活质量和儿科 HCT 患者的生存；以及 V) 促进研究和临床的网络和合作24 涉及儿童 HCT 患者的试验的结果可能会在第十届 PTCTC 教育会议上公布。增强我们对儿科科学研究的基础、转化和临床状态的理解- 特定的 cGVHD，这将为年轻人和老年人提供参与的机会和平台组委会将尽一切努力加强科学家的合作研究。通过增加来自不同背景的个人（包括来自代表性不足群体的个人）来实现多样性。通过旅行奖励特别鼓励受训人员和代表性不足的少数群体的参与。